The National Institutes of Health's National Cancer Institute is offering a license for a human T-cell line known as C8166-45, which is transformed by HTLV-1. This cell line, also referred to as C63/CRII-2, has three active proviruses that can help in studying T-cell growth and immortalization. The effective date for this notice is June 25, 2026.
The availability of the C8166-45 T-cell line for licensing provides researchers with a valuable tool for studying T-cell behavior, which could lead to better cancer treatments. The June 25, 2026, effective date allows time for interested parties to prepare their applications.
SIGNA Wire provides informational summaries of official government filings. Not investment advice.